CG Oncology (CGON) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Buy | $85.00 from $82.00 | Aug 7, 2026 |
| Piper Sandler | Maintained | Overweight | $85.00 from $82.00 | Aug 7, 2026 |
| RBC Capital | Maintained | Outperform | $79.00 from $81.00 | Aug 7, 2026 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | May 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 | May 18, 2026 |
| Truist Securities | Maintained | Buy | $82.00 from $77.00 | May 14, 2026 |
| Wedbush | Maintained | Outperform | $80.00 from $77.00 | May 11, 2026 |
| Truist Securities | Maintained | Buy | $77.00 from $75.00 | May 11, 2026 |
| RBC Capital | Maintained | Outperform | $81.00 from $79.00 | May 11, 2026 |
| JP Morgan | Maintained | Overweight | $96.00 from $91.00 | May 11, 2026 |
| RBC Capital | Maintained | Outperform | $79.00 from $73.00 | Apr 27, 2026 |
| JP Morgan | Maintained | Overweight | $91.00 from $65.00 | Apr 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 from $80.00 | Apr 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $80.00 from $75.00 | Feb 27, 2026 |
| Truist Securities | Maintained | Buy | $75.00 from $66.00 | Feb 10, 2026 |
| RBC Capital | Maintained | Outperform | $73.00 from $61.00 | Jan 21, 2026 |
| Piper Sandler | Maintained | Overweight | $70.00 from $55.00 | Jan 16, 2026 |
| Truist Securities | Maintained | Buy | $66.00 from $62.00 | Jan 12, 2026 |
| Wedbush | Initiated Coverage | Outperform | $70.00 | Dec 11, 2025 |
| Truist Securities | Initiated Coverage | Buy | $62.00 | Nov 24, 2025 |
Frequently asked questions
What is the price target for CGON stock?
The average 12-month analyst price target for CG Oncology (CGON) is $83.00, with a high estimate of $85.00 and a low of $79.00, across 3 analysts.
Is CGON a buy, sell, or hold?
Analysts covering CG Oncology currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CGON?
The average price target of $83.00 implies 10.43% upside from the last price of $75.16.
What is the latest analyst rating on CGON?
On Aug 7, 2026, Truist Securities maintained CG Oncology at Buy with a price target of $85.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.